Drug Development

With an oversubscribed $130M Series B, Crystalys Therapeutics is accelerating its gout drug, dotinurad. But can it win the race to serve millions?

With UK approval for its FLAMINGO-01 trial, Greenwich LifeSciences partners with a top cancer center, signaling a key move in the race to prevent breast cancer recurrence.

Biotech firm ReBio Pharma appoints world-renowned expert Prof. Mandeep Sagoo as CMO, accelerating its novel RBP-01 therapy for uveal melanoma into the clinic.

D&D Pharmatech's zabopegdutide shows fast liver improvement independent of weight loss, a key differentiator in the crowded, multi-billion dollar MASH market.

Peer-reviewed data confirms Telix's theranostic approach for advanced prostate cancer, de-risking its Phase 3 trial and setting the stage for a new competitor.

New preclinical data shows atebimetinib outmaneuvers older drugs by hitting cancer hard, then resting. Is this the key to durable tumor control and resilience?

A Boston biotech is making waves with a novel drug and a rapid-screening platform, a one-two punch designed to eliminate drug-resistant cancer stem cells.

San Diego's VivoSim Labs enters China, leveraging AI-powered human tissue models that challenge traditional animal testing and aim for safer, faster drug development.

SOTIO Biotech's European patent win for its immunocytokine SOT201 wasn't just a legal victory; it's a signpost in the fierce race to redefine cancer care.

Lonza licenses its elite ADC tech to Engitix, a biotech targeting the hidden battlefield of the extracellular matrix. A quiet move with loud implications.

Jupiter Neurosciences' $100M deal for a novel MDMA drug signals a major strategic shift, betting on a new era of psychedelic medicine in the U.S.

Avaí Bio's new deal for its Insulinova therapy brings a mysterious, world-class partner to the table, signaling a major step toward a functional cure for diabetes.

At AIDS 2026, ViiV Healthcare unveils data challenging treatment norms, proving long-acting injectable efficacy, and paving the way for quarterly PrEP.

Berlin-based OMEICOS gets a major FDA boost, advancing its novel PMD drug OMT-28 directly to a pivotal Phase 3 trial. A deep dive into the science.

Arcturus Therapeutics heads to the Canaccord Growth Conference to spotlight its advanced mRNA platform, shifting focus from COVID vaccines to rare diseases.

New research reveals how IntraBio's AQNEURSA recalibrates cellular function, a novel mechanism that could revolutionize treatment for a wide range of diseases.

A Rwandan-owned company reports promising results for a long-acting TB drug. It could transform treatment, but it also signals a shift in global health innovation.

A new study validates Actinogen's cortisol-inhibiting drug for depression, creating a strategic tailwind for its primary Alzheimer's program due in November.

Dogwood Therapeutics hits a critical trial milestone for its non-opioid pain drug, signaling a potential breakthrough for millions of cancer survivors.

With promising new data, Nuvation Bio is launching a bold, multi-front clinical strategy for its brain cancer drug. Is this the move that will outmaneuver competitors?